Kilarski W W, Bikfalvi A
Institut National de la Santé et de la Recherche Médicale E0113, Molecular Mechanisms of Angiogenesis, University Bordeaux I, Avenue des Facultés, 33405 Talence, France.
Curr Pharm Biotechnol. 2007 Feb;8(1):3-9. doi: 10.2174/138920107779941444.
Angiogenesis is a developmental process that also plays the central role in adults during the female menstruation cycle, wound healing and neoplastic growth and metastasis. Ideally, blocking neovessel growth starves the developing tumor and induces tumor regression. Restricting the vascular ingrowth into the tumor might have adverse effect on drugs targeting the tumor. Nevertheless, anti-VEGF treatment of the neoplastic diseases when combined with chemotherapy significantly increases median survival in treated patients. This suggests alternative mechanisms of anti-angiogenesis therapy. A number of molecules that are in current clinical trials have been identified using angiogenesis models. However, current angiogenesis models have advantages and inconvenience and conclusion drawn upon their use should be interpreted with caution. Thus, it is necessary to optimize existing models and to develop new ones that take into account the complexity of the angiogenic process as it happens in many angiogenesis-related diseases and in particular in cancer.
血管生成是一个发育过程，在成年女性的月经周期、伤口愈合以及肿瘤生长和转移过程中也起着核心作用。理想情况下，阻断新血管生长会使正在发育的肿瘤缺乏营养并诱导肿瘤消退。限制血管长入肿瘤可能会对靶向肿瘤的药物产生不利影响。然而，抗血管内皮生长因子（VEGF）治疗肿瘤疾病与化疗联合使用时，可显著提高接受治疗患者的中位生存期。这提示了抗血管生成治疗的其他机制。目前正在进行临床试验的许多分子都是利用血管生成模型鉴定出来的。然而，当前的血管生成模型既有优点也有不便之处，基于这些模型得出的结论应谨慎解读。因此，有必要优化现有模型并开发新模型，以考虑血管生成过程在许多与血管生成相关的疾病尤其是癌症中所呈现的复杂性。
